F10.2
Conditions
Interventions
Group 1: 24 IE Oxytocin intranasal
After receiving the intranasal medication the fMRI take place (Duration: 35 minutes)
Group 2: Intranasal Placebo
After receiving the intranasal medication the fMRI t
Sponsors
Zentralinstitut für Seelische GesundheitKlinik für Abhängiges Verhalten und Suchtmedizin
Eligibility
Sex/Gender
Male
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: - Age: Between 18 and 65 years - male gender - Fully Informed Consent - ability to take part in a fMRI - Written Informed Consent - Minimum 2 drinking days per week
Exclusion criteria
Exclusion criteria: - No fully Informed Consent - No written Informed Consent - Female gender - Age under 18 years ord over 65 years - psyciatric disorders of axis I (according to DSM IV or ICD 10 except for nicotine dependence. - Severe iinternal and neurological comorbities - medication with interacts with oxytocin - current drug abuse/dependence except for nicotine - alcoholization at the measuring days -contraindications for fMRI .
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Primary end point: Differences in the functional brain activity between the oxytocin and the placebo condition during confrontation with alcohol associated cues | — |
Secondary
| Measure | Time frame |
|---|---|
| Secunary end point: Differences in subjective craving between the oxytocin and the placebo condition during confrontation with alcohol associated cues (as measured with a visual analoge scale) | — |
Countries
Germany
Contacts
Public ContactAnne Koopmann
Zentralinstitut für Seelische GesundheitKlinik für Abhängiges Verhalten und Suchtmedizin
Outcome results
None listed